Telnyx Launches “LiveKit on Telnyx” for Deploying Voice AI Agents with Lower Cost and Ultra-Low Latency Basilea to become a leading anti-infectives company backed by strong financial results 2021
65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2…
Nano One Successfully Completes Phase One of its Co-Development Agreement with Niobium Producer CBMM
Nano One successfully completed Phase One of its co-develop work with CBMM Durability enhanced single…
NetCents Technology Changes Auditors
Vancouver, British Columbia–(Newsfile Corp. – February 15, 2022) – NetCents Technology Inc. (CSE: NC) (FSE:…
Xigem’s Cylix Data Corporation to Launch Next Generation of Business Risk Product
Powerful New Platform will be a One-Stop Shop for Business Risk Intelligence Toronto, Ontario–(Newsfile Corp….
Uptime Institute Launches Standardized, Comprehensive Infrastructure Risk Assessment for the Financial Sector
Assessment designed to help FSIs identify and mitigate digital infrastructure risk and support regulatory compliance…
Genuv Teams With Aiforia to Create an AI-Powered Version of its ATRIVIEW® Drug Screening Platform
ATRIVIEW® AI Platform Enables Faster and More Consistent Screening of Molecules That Demonstrate Neuroprotective and…
CrowdStrike’s Annual Threat Report Reveals Uptick Around Ransomware and Disruptive Operations; Exposes Evolution of eCrime Ecosystem
Report reveals adversaries adopt the use of “lock-and-leak” operations; identifies expanded targeting of Cloud Service…
ACI Worldwide Launches Innovative Global BNPL Solution With Access to 70+ BNPL Lenders via Single Integration
Innovative user interface a boon for merchants; provides higher BNPL acceptance rates and opportunity to…
BSO becomes fastest connectivity provider to the Mexican Stock Exchanges
Dublin, Ireland, 15 February, 2022 BSO, a global pioneering infrastructure and connectivity provider, has today…
Netacea announces $12m Series A investment
New funding from high profile cybersecurity leaders will grow Netacea’s presence in U.S. and U.K….
Hampleton Partners advises Apostera on its acquisition by HARMAN
Munich, Germany, and Novi, Mich. – 15 February 2022. Hampleton Partners, the international M&A and…
Kogenta, led by John Aalbers, merges fluxLoop and Urban Analytics, creating a world leading location and movement data analytics company
First dedicated Extract, Transform and Load (ETL) platform for complex location and movement data analytics,…
NMD Pharma Raises €35 Million in a new Financing
NMD Pharma Raises €35 Million in a new Financing – New investor Jeito Capital joins…
Aleafia Health Reports Q4 2021 Financial Results with $11.5 Million Branded Cannabis Gross Revenue, representing a 103% Increase from 2020
Transforming business towards a branded cannabis provider, with branded revenue representing 80% of total net…
CoinDCX Enhances Anti-Money Laundering Protection, Announces Partnership With Cryto-native Trade Surveillance And Market Integrity Leader Solidus Labs
An industry-first in India, CoinDCX leverages Solidus Labs’ machine-learning detection models to strengthen trust and…
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and…
ECMOHO Increases Digital Marketing Efforts To Drive Growth
SHANGHAI, China, Feb. 15, 2022 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the…
The Essential Coin Continues to Make Inroads in Their Mission to Be Next Big Cryptocurrency
Dallas, Texas–(Newsfile Corp. – February 14, 2022) – The Essential Coin is proud to announce…
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC)…
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience…